Cardiotropic AAV gene therapy for heart failure: a phase 1 trial

Area of Science:

• Cardiology
• Gene Therapy
• Translational Medicine

Background:

• Heart failure necessitates innovative treatments beyond current therapies to improve ventricular function.
• AB-1002, a viral vector gene therapy, has shown promise in preclinical heart failure models.
• Protein phosphatase 1 inhibitor 1 delivery aims to reverse cardiac dysfunction.

Purpose of the Study:

• To assess the safety and feasibility of AB-1002 gene therapy via coronary infusion.
• To evaluate AB-1002 in patients with severe nonischemic cardiomyopathy (NYHA Class III, LVEF 15-35%).

Main Methods:

• Phase 1 clinical trial involving two dose cohorts (3.25 × 10^13 and 1.08 × 10^14 viral genomes).
• Single antegrade coronary artery infusion of AB-1002.
• Safety, tolerability, and preliminary efficacy endpoints were monitored.

Main Results:

• No treatment-related adverse events (AEs) or serious AEs were reported; most AEs were mild/moderate.
• Mild, asymptomatic liver enzyme elevations occurred, mainly in the higher dose cohort.
• Preliminary efficacy suggested improvements in NYHA class, LVEF, peak oxygen consumption, and 6-minute walk test.

Conclusions:

• AB-1002 gene therapy appears safe and feasible for patients with severe heart failure.
• Preliminary efficacy data support continued clinical evaluation of AB-1002.
• Further trials are warranted to confirm the therapeutic potential of AB-1002.